### STREGA Reporting Recommendations, Extended from STROBE Statement

| Item | Item No | Description | Reported on Page Number/Line Number | Reported on Section/Paragraph |
|------|---------|-------------|-------------------------------------|------------------------------|
| **Title and Abstract** | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract.  
(b) Provide in the abstract an informative and balanced summary of what was done and what was found. | Page 1/ Line 1 | Title |
| **Introduction** | 2 | Explain the scientific background and rationale for the investigation being reported. | Page 3/ Line 62 | Introduction/Paragraph 2 |
| **Objectives** | 3 | State specific objectives, including any pre-specified hypotheses.  
*State if the study is the first report of a genetic association, a replication effort, or both.* | Page 3/ Line 73 | Introduction/Paragraph 3 |
| **Methods** | 4 | Present key elements of study design early in the paper. | Page 3/ Line 95 | Data source and preprocessing/Paragraph 2 |
| **Setting** | 5 | Describe the setting, locations and relevant dates, including periods of recruitment, exposure, follow-up, and data collection. | Page 3/ Line 99 | Data source and preprocessing/Paragraph 2 |
| **Participants** | 6 | (a) **Cohort study** – Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up.  
**Case-control study** – Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls.  
**Cross-sectional study** – Give the eligibility criteria, and the sources and methods of selection of participants.  
*Give information on the criteria and methods for selection of subsets of participants from a larger study, when relevant.*  
(b) **Cohort study** – For matched studies, give matching criteria and number of exposed and unexposed.  
**Case-control study** – For matched studies, give matching criteria and the number of controls per case. | Page 4/ Line 103 | Data source and preprocessing/Paragraph 2 |
| **Variables** | 7 | (a) Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.  
(b) Clearly define genetic exposures (genetic variants) using a widely-used nomenclature system. Identify variables likely to be associated with population stratification (confounding by ethnic origin). | Page 4/ Line 118 | Enzalutamide-related genes/Paragraph 1 |
| Data sources/ measurement | (a) For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group.  
(b) Describe laboratory methods, including source and storage of DNA, genotyping methods and platforms (including the allele calling algorithm used, and its version), error rates and call rates. State the laboratory/centre where genotyping was done. Describe comparability of laboratory methods if there is more than one group. Specify whether genotypes were assigned using all of the data from the study simultaneously or in smaller batches. | Page 4/ Line 128 | Protein–protein interaction network analysis/Paragraph 1 |
| Bias | (a) Describe any efforts to address potential sources of bias.  
(b) or quantitative outcome variables, specify if any investigation of potential bias resulting from pharmacotherapy was undertaken. If relevant, describe the nature and magnitude of the potential bias, and explain what approach was used to deal with this. | Page 5/ Line 130 | Protein–protein interaction network analysis/Paragraph 1 |
| Study size | Explain how the study size was arrived at. | Page 5/ Line 145 | Validation of the |
| Quantitative variables | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why.  
(if applicable, describe how effects of treatment were dealt with.) | Page 5/ Line 162 | Exploration of the associations with immune/Paragraph 1 |
| Statistical methods | (a) Describe all statistical methods, including those used to control for confounding.  
[State software version used and options (or settings) chosen.] | Page 6/ Line 176 | Statistical analysis/Paragraph 1 |
| | (b) Describe any methods used to examine subgroups and interactions. | Page 6/ Line 176 | Statistical |
| | (c) Explain how missing data were addressed. | Page 6/ Line 177 | Statistical |
| | (d) Cohort study – If applicable, explain how loss to follow-up was addressed.  
Case-control study – If applicable, explain how matching of cases and controls was addressed.  
Cross-sectional study – If applicable, describe analytical methods taking account of sampling strategy. | Page 6/ Line 177 | Statistical analysis/Paragraph 1 |
| | (e) Describe any sensitivity analyses. | Page 6/ Line 178 | Statistical |
| | (f) State whether Hardy-Weinberg equilibrium was considered and, if so, how. | - | - |
| | (g) Describe any methods used for inferring genotypes or haplotypes. | - | - |
| | (h) Describe any methods used to assess or address population stratification. | - | - |
| | (i) Describe any methods used to address multiple comparisons or to control risk of false positive findings. | Page 6/ Line 178 | Statistical |
| | (j) Describe any methods used to address and correct for relatedness among subjects | Page 6/ Line 178 | Statistical |
### Results

#### Participants 13*

- (a) Report the numbers of individuals at each stage of the study – e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed. *(Report numbers of individuals in whom genotyping was attempted and numbers of individuals in whom genotyping was successful).*  
  
- (b) Give reasons for non-participation at each stage.  
- (c) Consider use of a flow diagram.  

| Page/Line | Identification of enzalutamide-related genes/Paragraph 1 |
|-----------|----------------------------------------------------------|
| 6/ Line 184 | Results/Paragraph 1 |

#### Descriptive data 14*

- (a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders. *(Consider giving information by genotype.)*  
- (b) Indicate the number of participants with missing data for each variable of interest.  
- (c) **Cohort study** – Summarize follow-up time (e.g., average and total amount).  

| Page/Line | Development of PPI network/Paragraph 1 |
|-----------|---------------------------------------|
| 7/ Line 203 | Development of PPI |

#### Outcome data 15*

- **Cohort study** – Report numbers of outcome events or summary measures over time. *(Report outcomes (phenotypes) for each genotype category over time)*  
- **Case-control study** – Report numbers in each exposure category, or summary measures of exposure. *(Report numbers in each genotype category)*  
- **Cross-sectional study** – Report numbers of outcome events or summary measures. *(Report outcomes (phenotypes) for each genotype category)*  

| Page/Line | Determination of hub genes/Paragraph 1 |
|-----------|---------------------------------------|
| 7/ Line 211 | Determination of hub genes/Paragraph 1 |

#### Main results 16

- (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence intervals). Make clear which confounders were adjusted for and why they were included.  
- (b) Report category boundaries when continuous variables were categorized.  
- (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period.  
- (d) Report results of any adjustments for multiple comparisons.  

| Page/Line | Validation of the association with immune infiltration |
|-----------|-------------------------------------------------------|
| 8/ Line 264 | Validation of the association with immune infiltration |

#### Other analyses 17

- (a) Report other analyses done – e.g., analyses of subgroups and interactions, and sensitivity analyses.  
- (b) If numerous genetic exposures (genetic variants) were examined, summarize results from all analyses undertaken.  
- (c) If detailed results are available elsewhere, state how they can be accessed.  

| Page/Line | Immune infiltration |
|-----------|---------------------|
| 9/ Line 273 | Immune infiltration |

#### Discussion

- **Key results** 18
  
  Summarize key results with reference to study objectives.  

| Page/Line | Discussion Paragraph 1 |
|-----------|-------------------------|
| 9/ Line 289 | Discussion Paragraph 1 |

---
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias. | Page 9/ Line 295 | Discussion/ Paragraph 2 |
| Interpretaion | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence. | Page 9/ Line 295 | Discussion/ Paragraph 2 |
| Generalizability | 21 | Discuss the generalizability (external validity) of the study results. | Page 10/ Line 305 | Discussion/ Paragraph 3 |

**Other Information**

| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based. | Page 11/ Line 356 | Acknowledgments/Paragraph 1 |

* Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

From: Little J, Higgins JPT, Ioannidis JPA, Moher D, Gagnon F, et al. (2009) STrengthening the REporting of Genetic Association Studies (STREGA)—An extension of the STROBE Statement. PLoS Med 6(2): e1000022. doi:10.1371/journal.pmed.1000022

* Article information: https://dx.doi.org/10.21037/atm-21-6191
* As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.